Sergey Terushkin, MD, FACS Like all prescription medications, GLP-1 and GLP-1/GIP treatments may cause side effects
Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, affects gastric emptying by slowing the movement of food through the stomach
Compounded medications are regulated at the state level under less intensive oversight, reducing compliance costs
While not everyone experiences this side effect, a significant number of patients report a period of lethargy as their system recalibrates to a new metabolic set point. The relationship between GLP-1 GIP receptor agonists and energy levels Tirzepatide is a dual agonist, meaning it mimics two different hormones in the body: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
If the prescribed MOUNJARO presentation changes, ensure patients and caregivers receive appropriate training and instruct them to consult the Instructions for Use for the newly prescribed presentation
We unpack all that, including a Semaglutide weight loss dosage chart in this article to help you navigate your journey with Semaglutide and Compounded Semaglutide
